Australia
Austria
Belgium
China
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
India
Ireland
Italy
Japan
Kazakhstan
Latvia
Lithuania
Malaysia
Netherlands
Norway
Poland
Singapore
Slovenia
Spain
Sweden
Switzerland
Thailand
UK
Ukraine
Discover our science and innovation
Explore our news and stories
All articles
Orion Pharma invests in strengthening pharmaceutical manufacturi...
10/6/2026
Orion Pharma and Society
“This is a researcher's dream” – How a prostate cancer medicine ...
9/4/2026
Science and Partnering
A technical career at Orion Pharma – Technical expertise is need...
8/10/2026
We are Orion Pharma
The Veturi research ecosystem led by Orion: Personalised medicin...
6/15/2026
Science and Partnering
A stable society does not appear out of the blue – Orion and CMI...
5/11/2026
Interim Report January-September 2026
Orion will publish Interim Report for January–September 2026 on Wednesday, 28 October 2026 at approximately 12.00 noon EET.
Read the report
Stock exchange releases
- 10/7/2026 125,000 Orion Corporation A shares converted into B shares
- 9/30/2026 Orion Corporation completed share acquisitions
- 9/30/2026 Orion Corporation: Acquisition of own shares during week 40, 2026
- 9/25/2026 Orion Corporation: Acquisition of own shares during week 39, 2026
Press releases
- 10/14/2026 Orion publishes Interim Report for January–September 2026 and holds a webcast on 28 October 2026
- 10/6/2026 Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market
- 10/5/2026 Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing
- 7/3/2026 Orion publishes Half-Year Report for January–June 2026 and holds a webcast on 17 July 2026
Sustainability at Orion Pharma
Our operations help to build the well-being of people, animals and society. At the same time, we strive to minimise the impact of our operations on the environment.
Read more
